Sequential, increased deletion of BACE1 in adult AD mouse model reversed amyloid deposition
WEDNESDAY, Feb. 14, 2018 (HealthDay News) — Sustained and increasing BACE1 inhibition can reverse amyloid deposition in a mouse model of Alzheimer’s disease (AD), according to a study published online Feb. 14 in the Journal of Experimental Medicine.
Noting that BACE1 initiates the generation of the β-amyloid peptide, Xiangyou Hu, Ph.D., from the Cleveland Clinic, and colleagues generated conditional knockout BACE1fl/fl mice and bred them with ubiquitin-CreER mice to induce BACE1 deletion after early developmental stages.
The researchers found that amyloid deposition was completely reversed with sequential and increased deletion of BACE1 in an adult AD mouse model. Significant improvement in gliosis and neuritic dystrophy was seen with this reversal in amyloid deposition. In addition, there was significant improvement in synaptic functions, as determined by long-term potentiation and contextual fear conditioning experiments, in association with the reversal of amyloid plaques.
“Our results demonstrate that sustained and increasing BACE1 inhibition in adults can reverse amyloid deposition in an AD mouse model, and this observation will help to provide guidance for the proper use of BACE1 inhibitors in human patients,” the authors write.
More Extensive Deposits of Tau Seen in Early-Onset Alzheimer Disease 
NOACs Linked to Slower Cognitive Decline in Patients With A-Fib, Alzheimer Disease 
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women 
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia 
AI Better Assesses Heart Function From MRI Than Clinicians 
CTE Pathology Found in Nearly 75 Percent of Deceased Former NFL Players 
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026 
Lower Vertebral Bone Mineral Density Linked to Cognitive Decline 
